Search form

Search

Navigation

home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
Legal Help
login/register

You are here

Home » companies » T-ALL

T-ALL

Beam Therapeutics starts dosing in phase 1/2 trial of BEAM-201 in relapsed, refractory T-ALL/T-LL

Benzinga

Tue, 09/5/23 - 11:28 am

Beam Therapeutics

clinical trials

news tags

AbbVie Allergan Alzheimer's disease Amgen AstraZeneca Biogen biotech Bristol-Myers Squibb cancer Celgene China clinical trials COVID-19 devices diabetes drug pricing earnings Eli Lilly Europe FDA generics Gilead Sciences GSK IPOs JNJ layoffs M&A Medtech Medtronic Merck Novartis Novo Nordisk patents Pfizer Pharma CEOs R&D Regeneron Roche Sanofi vaccines

privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter

Copyright © 2025,